𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Surge in results for Henkel in Jan-Sep 2007

Book ID
114376316
Publisher
Elsevier Science
Year
2008
Weight
54 KB
Volume
2008
Category
Article
ISSN
1351-4210

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Favourable results for Henkel in 1Q 2002
Favourable results for Henkel in 1Q 2002
πŸ“‚ Article πŸ“… 2002 πŸ› Elsevier Science βš– 39 KB

The increase in the net loss primarily reflects clinical trial costs incurred for the company's lead product, Surfaxin, currently in three Phase III trials and one Phase II trial. Selected updates on the company's progress in 1Q 2002 are included in the report. Revenues from collaborative agreements

Balanced results for Henkel in 2008. Hig
Balanced results for Henkel in 2008. High restructuring costs burden results
πŸ“‚ Article πŸ“… 2009 πŸ› Elsevier Science βš– 61 KB

biological agriculture (BioAg) delivered higher growth than expected. Biopharmaceutical ingredients (BPI) experienced a decline of 1% in LCY. Financial results data are tabulated and graphically illustrated.